文献速递淋巴瘤

基因突变与384例初治慢性淋巴细胞白血病患者首次治疗时间的关系

Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients.
PubMed 文献 · Br J Haematol · 2019-06-26

本研究在384例初治慢性淋巴细胞白血病(CLL)患者中,分析体细胞突变与已知预后因素和首次治疗时间(TTFT)的关联。单变量分析显示,突变ATM、NOTCH1、SF3B1及未突变IGHV、del(11q)、12三体、晚期Rai/Binet分期与较短TTFT相关;而del(17p)、突变TP53和复杂核型与TTFT无关。多变量分析中,突变ATM和未突变IGHV仍显著。

要点

  • 突变ATM、NOTCH1、SF3B1及未突变IGHV、del(11q)、12三体与较短TTFT相关。
  • del(17p)、突变TP53和复杂核型与TTFT无显著关联。
  • 多变量分析中突变ATM和未突变IGHV仍与较短TTFT显著相关。

核心结论

  • 突变ATM和未突变IGHV与初治CLL患者较短TTFT显著相关,提示其在早期白血病发生中重要。
  • del(17p)、突变TP53和复杂核型与TTFT无显著关联,提示这些异常在早期疾病进展中作用有限,而在复发CLL中更重要。

研究设计与样本

  • 研究纳入384例初治CLL患者,对来自外周血或骨髓的CLL DNA进行29基因靶向二代测序。
  • 分析基因突变数据与同期临床特征(Rai/Binet分期、FISH、ZAP70/CD38、核型、IGHV突变状态),采用单变量和多变量分析识别与TTFT的关联。
  • TTFT定义为从诊断至首次治疗的时间。

主要发现

  • 单变量分析中,突变ATM(P < 0·001)、NOTCH1(P < 0·001)、SF3B1(P = 0·002)、未突变IGHV(P < 0·001)、del(11q)(P < 0·001)、12三体(P < 0·001)、晚期Rai分期(P = 0·05)和Binet分期(P < 0·001)与较短TTFT相关。
  • 单变量分析中,del(17p)、突变TP53和复杂核型与较短TTFT无显著关联。
  • 多变量分析中,突变ATM(P < 0·001)和未突变IGHV状态(P < 0·001)仍显著。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study correlated somatic mutation results and known prognostic factors with time-to-first treatment (TTFT) in 384 treatment-naïve (TN) chronic lymphocytic leukaemia (CLL) patients to help determine disease-specific drivers of early untreated CLL. CLL DNA from either peripheral blood or bone marrow underwent next generation targeted sequencing with a 29-gene panel. Gene mutation data and concurrent clinical characteristics, such as Rai/Binet stage, fluorescence in situ hybridisation (FISH), ZAP70/CD38, karyotype and IGHV mutation, status were analysed in univariable and multivariable analyses to identify associations with TTFT. TTFT was defined as time from diagnosis to initial treatment. In univariable analyses, mutated ATM (P < 0·001), NOTCH1 (P < 0·001) and SF3B1 (P = 0·002) as well as unmutated IGHV (P < 0·001), del(11q) (P < 0·001) and trisomy 12 (P < 0·001) by hierarchal FISH and advanced Rai (P = 0·05) and Binet (P < 0·001) stages were associated with shorter TTFT. Importantly, del(17p), mutated TP53 and complex karyotype were not associated with shorter TTFT. In a reduced multivariable analysis, mutated ATM (P < 0·001) and unmutated IGHV status (P < 0·001) remained significant, showing their importance in early leukaemogenesis. High-risk prognostic markers such as del(17p), mutated TP53 and complex karyotype, were not correlated with TTFT, suggesting that these abnormalities have limited roles in early disease progression but are more important in relapsed CLL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Hu B, Patel KP, Chen HC, et al. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol. 2019. PMID: 31243771. doi:10.1111/bjh.16042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。